Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function

Blood

Volumn 102, Issue 13, 2003, Pages 4320-4325

  Nguyen, Phuong ^b   Moisini, Ioana ^b   Geiger, Terrence L ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD8 ANTIGEN; CHIMERIC PROTEIN; DILEUCINE; GAMMA INTERFERON; LEUCINE; MUTANT PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELL PROLIFERATION; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXICITY; DNA MODIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STRUCTURE; PROTEIN TARGETING; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 0344737701     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-04-1255     Document Type: Article

References (36)

1. Geiger TL, Jyothi MD. Development and application of receptor-modified T lymphocytes for adoptive immunotherapy. Transfus Med Rev. 2001;15:21-34.
2. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3:35-45.
3. Abken H, Hombach A, Heuser C, Sircar R, Pohl C, Reinhold U. Chimeric T-cell receptors: highly specific tools to target cytotoxic T-lymphocytes to tumour cells. Cancer Treat Rev. 1997;23:97-112.
4. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9:279-286.
5. Haynes NM, Trapani JA, Teng MW, et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol. 2002;169:5780-5786.
6. Kershaw MH, Westwood JA, Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol. 2002;20:1221-1227.
7. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects, Blood. 2000;96:785-793.
8. Lenschow D J, Walunas TL, Bluestone JA, CD28/B7 system of T cell costimulation. Annu Rey Immunol. 1996;14:233-258.
9. Watts TH, DeBenedette MA. T cell co-stimulatory molecules other than CD28. Curr Opin Immunol. 1999;11:286-293.
10. Geiger TL, Nguyen P, Leitenberg D, Flavell RA. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood. 2001;98:2364-2371.
11. Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol. 1998;161:2791-2797.
12. Hombach A, Wieczarkowiecz A, Marquardt T, et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol. 2001;167:6123-6131.
13. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol. 2002;20:70-75.
14. Warren EH, Gavin M, Greenberg PD, Riddell SR. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr Opin Hematol. 1998;5:429-433.
15. Waldmann H, Cobbold S, Hale G. What can be done to prevent graft versus host disease? Curr Opin Immunol. 1994;6:777-783.
16. Nguyen P, Geiger TL. Antigen-specific targeting of CD8(+) T cells with receptor-modified T lymphocytes. Gene Ther. 2003;10:594-604.
17. Alam SM, Davies GM, Lin CM, et al. Qualitative and quantitative differences in T cell receptor binding of agonist and antagonist ligands. Immunity. 1999;10:227-237.
18. Bonifacino JS, Traub LM. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu Rev Biochem. 2003;72:395-447.
19. Persons DA, Allay JA, Allay ER, et al. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood. 1997;90:1777-1786.
20. Geiger T, Gooding LR, Flavell RA. T-cell responsiveness to an oncogenic peripheral protein and spontaneous autoimmunity in transgenic mice. Proc Natl Acad Sci U S A. 1992;89:2985-2989.
21. Ausubel FM, Brent R, Kingston RE, et al. Current Protocols in Molecular Biology, New York, NY: John Wiley and Sons; 1989.
22. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity. 1998;8:89-96.
23. Lanzavecchia A, Lezzi G, Viola A. From TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell. 1999;96:1-4.
24. Hesiop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev. 1997;157:217-222.
25. Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol. 1999;27:1477-1486.
26. Brodie SJ, Patterson BK, Lewinsohn DA, et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest. 2000;105:1407-1417.
27. Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother. 1997;45:131-136.
28. Wels W, Moritz D, Schmidt M, Jeschke M, Hynes N, Groner B. Biotechnological and gene therapeutic strategies in cancer treatment. Gene. 1995;159:73-80.
29. Sandoval IV, Martinez-Arca S, Valdueza J, Palacios S, Holman GD. Distinct reading of different structural determinants modulates the dileucine-mediated transport steps of the lysosomal membrane protein LIMPII and the insulin-sensitive glucose transporter GLUT4. J Biol Chem. 2000;275:39874-39885.
30. von Essen M, Menne C, Nielsen BL, et al. The CD3 gamma leucine-based receptor-sorting motif is required for efficient ligand-mediated TCR down-regulation. J Immunol. 2002;168:4519-4523.
31. Pitcher C, Honing S, Fingerhut A, Bowers K, Marsh M. Cluster of differentiation antigen 4 (CD4) endocytosis and adaptor complex binding require activation of the CD4 endocytosis signal by serine phosphorylation. Mol Biol Cell. 1999;10:677-691.
32. Dietrich J, Kastrup J, Nielsen BL, Odum N, Geisler C. Regulation and function of the CD3gamma DxxxLL motif: a binding site for adaptor protein-1 and adaptor protein-2 in vitro. J Cell Biol. 1997;138:271-281.
33. Letourneur F, Klausner RD. A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains. Cell. 1992;69:1143-1157.
34. Wraith D, Smilek D, Mitchell D, Steinman L, McDevitt H. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide mediated immunotherapy. Cell. 1989;59:247-255.
35. Fink PJ, Shimonkevitz RP, Bevan MJ. Veto cells. Ann Rev Immunol. 1988;6:115-137.
36. Reich-Zeliger S, Zhao Y, Krauthgamer R, Bachar-Lustig E, Reisner Y. Anti-third party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity. 2000;13:507-515.